Answers are grounded in this paper and cite their sources.
Viewpoint discusses FDA's label updates and removal of warnings for menopausal hormone therapy, suggesting new implications for treatment.
This Viewpoint describes the US Food and Drug Administration’s intended label updates and removal of black box warnings for menopausal hormone therapy based on current evidence.
No takes yet. Share an insight, caveat, or question.
Makary et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: